Details of the Drug Reposition

General Information of This Drug (ID: DMTIGA0)

• Drug Name: Acrivastine (DMTIGA0)
• Synonyms: Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
• Therapeutic Class: Antiinflammatory Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

2 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Common cold	DIS3MADM	CA00	Approved	[1]
Vasomotor/allergic rhinitis	DISHSTQ0	CA08	Approved	[1]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Allergic conjunctivitis	DISZ5ZJN	9A60.02	Withdrawn	[2]

References

• [1] Acrivastine FDA Label
• [2] Lithium and Acetate for Canavan Disease